跳轉至內容
Merck
全部照片(1)

文件

C2163000

环孢素

European Pharmacopoeia (EP) Reference Standard

同義詞:

环孢菌素A, 抗生素S 7481F1, 环孢霉素

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C62H111N11O12
CAS號碼:
59865-13-3
分子量：:
1202.61
Beilstein:
3647785
MDL號碼:
MFCD00274558
分類程式碼代碼:
41116107
PubChem物質ID:
329774971
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

ciclosporin

製造商／商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C

InChI

1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1

InChI 密鑰

PMATZTZNYRCHOR-CGLBZJNRSA-N

基因資訊

human ... PPIA(5478)

尋找類似的產品？ 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Ciclosporin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化／生理作用

一种具有强大的免疫抑制特性的真菌代谢物。它通过形成抑制钙调神经磷酸酶（蛋白磷酸酶 2B）的环孢菌素A−亲环蛋白复合物来抑制 T 细胞受体的信号转导途径。抑制由白介素1α、脂多糖和TNFα诱导的一氧化氮合成。阻止线粒体释放细胞色素 c。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazardExclamation mark
GHS08,GHS07

訊號詞

Danger

危險聲明

H302,H350,H360FD

危險分類

Acute Tox. 4 Oral - Carc. 1B - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 3

1 of 3

环孢菌素A 溶液 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-093

环孢菌素A 溶液

他克莫司 Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1809

他克莫司

他克莫司 United States Pharmacopeia (USP) Reference Standard

USP

1642802

他克莫司

Marcel B M Teunissen et al.
The Journal of investigative dermatology, 134(12), 2898-2907 (2014-06-20)
IL-17A is pivotal in the etiology of psoriasis, and CD8(+) T cells with the ability to produce this cytokine (Tc17 cells) are over-represented in psoriatic lesions. Here we demonstrate that the frequency of Tc17 cells in peripheral blood of psoriasis
Anne I Dipchand et al.
Pediatric transplantation, 18(7), 764-770 (2014-08-15)
Cardiac remodeling is associated with plasma biomarkers of fibrinogenesis, inflammation, and oxidative stress, and upregulation of mitogenic, pro-fibrotic, and apoptotic signaling pathways. Our primary objective was to evaluate biomarker and subcellular myocardial changes in pediatric heart transplant recipients. Fifty-two-week prospective
Yasuo Morishima et al.
Blood, 125(7), 1189-1197 (2014-12-19)
We hypothesized that the compatibility of each HLA loci between donor and patient induced divergent transplant-related immunologic responses, which attributed to the individualized manifestation of clinical outcomes. Here, we analyzed 7898 Japanese pairs transplanted with T-cell-replete marrow from an unrelated
Angela C Webster et al.
BMJ (Clinical research ed.), 331(7520), 810-810 (2005-09-15)
To compare the positive and negative effects of tacrolimus and ciclosporin as initial treatment for renal transplant recipients. Systematic review. Reports of comparative randomised trials of tacrolimus and ciclosporin identified by searches of Medline, Embase, the Cochrane Register of Controlled
K J Tinckam et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 15(2), 417-426 (2015-01-24)
Donor-specific HLA antibodies (DSA) have an adverse effect on short-term and long-term lung transplant outcomes. We implemented a perioperative strategy to treat DSA-positive recipients, leading to equivalent rejection and graft survival outcomes. Pretransplant DSA were identified to HLA-A, B, C
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務